Vericel Corp. (Nasdaq: VCEL) Up in Pre-Market!

Market Mover Alert! Vericel Corporation – Nasdaq: VCEL

Pre-market activity in shares of Cambridge, MA based Vericel Corporation is heavy. VCEL trades on the Nasdaq and closed Tuesday at $2.60 but today’s pre-market activity has seen the shares reach as high as $4.75 on large volumes. Traders appear to be responding to today’s news that Vericel Corporation has received FDA approval for MACI – an orthopedic treatment for repairing certain cartilage defects in the knee.  

According to Vericel’s Corporation’s press release, David Recker, MD, chief medical officer of Vericel stated: 

While orthopedic surgeons have long understood that autologous chondrocyte implantation can regenerate cartilage tissue, the previous surgical procedure was technically complex and time consuming, and the indicated patient population was limited.  MACI is the first product to show a statistically significantly greater improvement in KOOS pain and function scores compared to microfracture, a commonly performed alternative surgical treatment for cartilage repair, in a well-controlled Phase 3 clinical study.  With the introduction of MACI, orthopedic surgeons will have a simplified treatment option available for a broader patient population supported by solid clinical evidence. 

VCEL began an upward swing in mid-November when the company released positive news on its Phase 2b clinical trial of Ixmyelocel-T; a drug designed to treat ventricular arrhythmia episodes. Taking today’s pre-market session into account, VCEL has more than doubles since it’s November lows around $2.00. Vericel has never had positive EPS, but they have managed to narrow the loss each year on successfully higher revenues. 

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

 

Ticker Symbol VCEL
Last Price a/o 8:20 EST  $               4.35
Average Volume 380,500
Market Cap $54.7 million
Sales $53.3 million
Shares Outstanding 21.05 million
Share Float 21.05 million
Shortable Yes
Optionable Yes
Inside Ownership 11.00%
Short Float 1.37%
Short Interest Ratio 0.76
Quarterly Return 8.80%
YTD Return 0.78%
Year Return 42.86%

 

Opthotech Corp (Nasdaq: OPHT) Shares Plunge

Market Mover Alert! Opthotech Corporation – Nasdaq ticker: OPHT

Shares of OPHT are down over 80% on large volumes. Opthotech Corporation announced that it did not meet its primary endpoints in a pivotal Phase 3 clinical trial. The trial was to measure the effectiveness of their drug candidate Fostiva in combination with Lucentis for the treatment of wet aged-related macular degeneration. Opthotech is a biopharmaceutical company specializing in the development of treatments to address diseases of the back of the eye.

On Friday OPHT closed at $38.77 but Monday’s close saw OPHT lows reaching $5.21. Such news underscores the risk inherent with biotechnology shares to the investment community.

From Opthotech’s press release:

“We are very disappointed in the results from these trials, particularly for patients afflicted with wet AMD,” commented David R. Guyer, M.D., Chief Executive Officer of Ophthotech. “We are thankful to the patients and clinical investigators and their staff for participating in the trials. We will continue to analyze the data from these two studies to better understand the trial results.”

Opthotech Corporation’s sales has grown from $0.00 in 2013 to $51.5 million in 2015. Several bulge-bracket investment banks cover OPHT and three this morning have downgraded the stock to “Neutral”.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol OPHT
Last Price a/o 3:52 EST  $               5.27
Average Volume 1 million
Market Cap $1.38 Billion
Sales $50.4 million
Shares Outstanding 35.6 million
Share Float 35.5 million
Shortable Yes
Optionable Yes
Inside Ownership 5.48%
Short Float 11.41%
Short Interest Ratio 3.97
Quarterly Return -28.70%
YTD Return -50.60%
Year Return -41.20%

 

General Finance Corp (Nasdaq: GFN) CEO Buys Shares

Market Mover Alert! General Finance Corp. – Nasdaq ticker: GFN

Shares of GFN are higher on large volumes. General Finance Corporation, located in Pasadena, CA, is a leading specialty rental services company that offers portable storage solutions globally. On December 7, 2016, they released Q1 results which included $62.8 million in revenues, a drop of $1 million from previous year’s Q1 figures. However General Finance Corp. CEO Ronald Valenta has recently acquired over 30,000 shares of GFN which seem to have motivated investors.

On December 2, shares ended the day at $4.05. Today GFN hit an intraday high of $4.95 on larger than normal volume.

From General Finance Corporation’s press release dated December 7, 2016:

First Quarter 2017 Highlights :

  • Total revenues were $62.8 million, compared to $63.8 million for the first quarter of fiscal year 2016.
  • Leasing revenues comprised 67% of total non-manufacturing revenues in both the first quarters of fiscal years 2017 and 2016.
  • Leasing revenues increased by 12%, excluding the oil and gas sector and the favorable foreign exchange impact.
  • Adjusted EBITDA was $13.0 million, compared to $13.9 million in the first quarter of fiscal year 2016.
  • Adjusted EBITDA margin was 21%, compared to 22% in the first quarter of fiscal year 2016.
  • Net loss attributable to common shareholders was $2.1 million, or $0.08 per diluted share, comparable to net loss attributable to common shareholders of $2.0 million, or $0.08 per diluted share, for the first quarter of fiscal year 2016.
  • Average fleet unit utilization was 73%, compared to 75% in the first quarter of fiscal year 2016.
  • Two acquisitions completed in North America during the quarter.

“Our North American leasing operations continued to benefit from geographic expansion and diversification,” said Ronald Valenta, President and Chief Executive Officer. “We delivered increased leasing revenues during the first quarter of fiscal year 2017 outside of the oil and gas sector. In September, we began to see positive signs in the energy sector, including increased drilling activity and improved fleet utilization. In the Asia-Pacific region, our non-oil and gas leasing revenues also increased, primarily driven by continued strength from the construction sector and a moderately higher Australian dollar relative to the U.S. dollar.”

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol GFN
Last Price 12/9/2016 11:30 EST  $               4.80
Average Volume 18,000
Market Cap $118 million
Sales $285 million
Shares Outstanding 26.3 million
Share Float 13.1 million
Shortable Yes
Optionable Yes
Inside Ownership 5.60%
Short Float 1.00%
Short Interest Ratio 7.15
Quarterly Return 3.69%
YTD Return 12.80%
Year Return 12.80%

Emcore Corp. (Nasdaq: EMKR) Exceeds Earnings Expectations

Market Mover Alert on Emcore Corporation – Nasdaq ticker: EMKR

Shares of Emcore Corporation jumped at the open based on their released earnings report. EMKR shares closed trading at $6.45 yesterday and hit a high of $8.70 this morning before pulling back on heavy volume. Emcore Corporation trades on the Nasdaq under the ticker EMKR.

Emcore Corporation makes products that transform the internet. Emcore designs and manufactures chips, components, and systems for the broadband and specialty fiber optics markets. Based in California, Emcore Corporation has offices in Pennsylvania, Europe, and China.

According to published reports, Emcore Corporation on Wednesday reported fiscal fourth-quarter earnings of $2 million. On a per-share basis, Emcore had net income of 7 cents. Earnings, adjusted for one-time gains and costs, were 10 cents per share of EMKR. $25.6 million in revenues exceeded expectations. Four analysts surveyed by Zacks expected $24.4 million. For the year, Emcore Corporation reported a profit of $8.3 million, or 31 cents per share of EMKR. Revenue was reported as $92 million. Three analysts that cover EMKR have either a “Buy” or “Outperform” on EMKR with price targets from $7.00 to $11.00.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol EMKR
Last Price a/o 10:45 EST  $               8.10
Average Volume 264,000
Market Cap $170 million
Sales $89.4 million
Shares Outstanding 26.35 million
Share Float 23.3 million
Shortable Yes
Optionable Yes
Inside Ownership 29.60%
Short Float 4.39%
Short Interest Ratio 3.88
Quarterly Return 27%
YTD Return 36.90%
Year Return 6.24%

 

Anthera Pharmaceuticals Inc (Nasdaq: ANTH) on the Move!

ANTH – Market Mover Alert!

Anthera Pharmaceuticals Inc., trading on the Nasdaq under ticker symbol ANTH, has seen a price a volume spike this morning. Anthera Pharmaceuticals recently elevated it President, Craig Thompson, to the Board level and to the position of CEO. Investors have responded to the news with volumes over ten time the normal trading volume in the first half-hour of trading; sending ANTH to an early morning gain of over 50%.

Anthera Pharmaceuticals Inc. is a California-based biotechnology company that focuses on innovative medicines. The company trades on the Nasdaq under the ticker symbol ANTH. They rely on two product candidates in development: Sollpura and Blisibimod. Sollpura is a biotechnology driven pancreatic replacement therapy for the potential treatment of exocrine pancreatic insufficiency in people suffering from cystic fibrosis. Blisibimod is a BAFF inhibitor for the potential treatment of systemic lupus erythematosus and IgA nephropathy. Company reports suggest that both drugs have made it through their respective Phase I and II clinical studies.

From Anthera Pharmaceuticals filing:

On December 2, 2016, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”), Anthera Pharmaceuticals, Inc. (the “Company”) appointed Craig Thompson to serve on the Board as a Class I director and to serve as the Company’s Chief Executive Officer, effective December 6, 2016. Mr. Thompson will also continue to serve as the Company’s President.

Mr. Thompson was appointed to serve as the Company’s President and Chief Operating Officer effective January 7, 2016. Mr. Thompson, 50, has over 20 years of experience in pharmaceutical development and commercialization. Most recently he served as the Chief Operating Officer for Tetraphase Pharmaceuticals from February 2014 to December 2015, where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing. Prior to Tetraphase Pharmaceuticals, from January 2011 to December 2014, Mr. Thompson served as the Chief Commercial Officer for Trius Therapeutics resulting in the acquisition of Trius by Cubist Pharmaceuticals for over $700 million. Prior to Trius Therapeutics, Mr. Thompson held various positions of increasing responsibility with Pfizer from November 2003 to December 2010, with his last position as Vice President of Marketing, Specialty Care. Prior to Pfizer he held various positions of increasing responsibility at Merck and Co, Inc. from April 1993 to November 2003. Mr. Thompson holds a Bachelor’s degree in Commerce from McMaster University and a Master’s degree in Business Administration from the University of Notre Dame.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data on ANTH is provided without any guarantee of its accuracy.

Ticker Symbol ANTH
Last Price a/o 9:45 EST  $               2.39
Average Volume 618,000
Market Cap $56 million
Sales $2.1 million
Shares Outstanding 38 million
Share Float 36.8 million
Shortable Yes
Optionable Yes
Inside Ownership 12.46%
Short Float 15.90%
Short Interest Ratio 9.46
Quarterly Return -51%
YTD Return -68%
Year Return -68.00%

Republic First Bancorp (Nasdaq: FRBK) Announcement Sends Shares/Volumes Higher

Republic First Bancorp, trading under the Nasdaq ticker FRBK, released news this morning that has seen an intraday price increase of over 30% since yesterday’s close of trading. Volumes have also exploded to the upside with current daily trading volume in excess of twelve times the average daily volume.

Republic First Bancorp, Inc. is the holding company of a full-service, state-chartered commercial bank that does business under the name Republic Bank through approximately nineteen branches in southern New Jersey and the greater Philadelphia, PA area. Deposits are insured up to the applicable limits by the Federal Deposit Insurance Corporation (FDIC).

Republic First Bancorp, Inc, the holding company for Republic Bank, today announced that it completed the sale of $100 million of its common stock at a price of $5.35 per share and elected Vernon W. Hill, II as a Director and Chairman of Republic First Bancorp, Inc. Mr. Hill is considered as a forward thinking retail banker and has a history in the sector that includes being the Founder of Chairman of Commerce Bancorps and Metro Bank (UK).

The additional capital will be utilized to expand the growth opportunities of Republic Bank through the addition of new stores, primarily in southern New Jersey and the surrounding Philadelphia area.  The Bank has opened eight new locations over the last three years using its signature glass building. There are plans for additional stores during 2017 in Cherry Hill, Medford, Sicklerville and Blackwood, NJ and Fairless Hills and Bensalem, PA.

Investors appear to approve of the developments. FRBK closed under $6.00 on December 5, 2016 and rose to close to $8.00 in today’s morning trading. Average volumes have typically been under 60,000 shares but volumes are over ten times that level in intra-day trading today.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol FRBK
Price $7.30
Average Volume 58k
Market Cap $230 million
Sales $52 million
Shares Outstanding 38.3 million
Share Float 31 million
Shortable Yes
Optionable Yes
Inside Ownership 30.00%
Short Float 3.86%
Short Interest Ratio 20.4
Quarterly Return 41%
YTD Return 39%
Year Return 33.00%

Neovasc Inc (Nasdaq: NVCN) Up Big in Early Trading

Shares of Neovasc Inc, trading on the Nasdaq under ticker NVCN, are up over 50% in early heavy trading. Neovasc Inc. is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.

This morning Neovasc Inc provided an update on its clinical experiences with its Tiara transcatheter mitral valve – a device that treats conditions that can lead to heart failure and death. Investors seem to welcome the news as NVCN volumes have exploded to over two million shares in early trading. NVCN ended yesterday with a closing price of around $1.42 but NVCN has traded over $2.00 today.

From NeoVasc Inc.’s press release:

To date, 22 patients have been treated with the Tiara™ valve at medical centers in Canada, the U.S. and Europe with more implantations scheduled for the coming weeks.  The technical success rate in these implantations was 19/22 or 86%.  In these technically successful implantations, paravalvular leak levels were reported as mild, trace or absent in 100% of these cases.  All cause 30-day mortality in the 19 patients who have reached 30 days post implant with Tiara™ is 15.7% (3/19).  The 3 remaining patients treated within the last 30 days are recovering well.  Of note, there has been no 30-day mortality reported in any of the last 8 patients treated over a month ago.  

Dr. Shmuel Banai, Neovasc Inc.’s Medical Director, presented the results at the ICI Meeting 2016 (ICI) in Tel Aviv, Israel.  ICI is the premier International Conference for Innovations in Cardiovascular Systems.

Information provided below is not guaranteed for its accuracy. As always perform your own due diligence before taking any action regarding any stocks. Biotechnology stocks are inherently risky.

Ticker Symbol NVCN
Price (EOD – ) $1.42
Average Volume 2.2 million
Market Cap $100 million
Sales $9.0 million
Shares Outstanding 67 million
Share Float 45 million
Shortable Yes
Optionable No
Inside Ownership 6.30%
Short Float 3.85%
Short Interest Ratio 0.81
Quarterly Return 141%
YTD Return -68.50%
Annual Return -66.00%